Option Care Health, Inc. (OPCH)
| Market Cap | 4.36B |
| Revenue (ttm) | 5.65B |
| Net Income (ttm) | 207.59M |
| Shares Out | 156.99M |
| EPS (ttm) | 1.27 |
| PE Ratio | 21.87 |
| Forward PE | 18.53 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,235,690 |
| Open | 28.10 |
| Previous Close | 27.93 |
| Day's Range | 27.67 - 28.24 |
| 52-Week Range | 24.24 - 36.80 |
| Beta | 0.95 |
| Analysts | Strong Buy |
| Price Target | 37.00 (+33.24%) |
| Earnings Date | Apr 30, 2026 |
About OPCH
Option Care Health, Inc. offers home and alternate site infusion services in the United States. The company provides anti-infective therapy and services; home infusion services to treat heart failure; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn’s disease, plaque psoriasis, psoriatic arth... [Read more]
Financial Performance
In 2025, Option Care Health's revenue was $5.65 billion, an increase of 13.03% compared to the previous year's $5.00 billion. Earnings were $207.59 million, a decrease of -2.00%.
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for OPCH stock is "Strong Buy." The 12-month stock price target is $37.0, which is an increase of 33.24% from the latest price.
News
Option Care Health Transcript: TD Cowen 46th Annual Health Care Conference
Exceeded 2025 targets and expanded patient reach, with a $25M-$35M headwind expected in 2026 due to therapy mix changes. Acute business is set for mid-single digit growth, supported by operational scale and advanced practitioner models, while capital deployment remains flexible.
Option Care Health Earnings Call Transcript: Q4 2025
Revenue grew 13% to $5.6B in 2025, with strong acute and chronic therapy growth and expanding payer partnerships. 2026 guidance reaffirms 4% revenue growth at midpoint, $480–505M adjusted EBITDA, and $340M+ operating cash flow, despite Stelara biosimilar headwinds.
Option Care Health Announces Financial Results for Fourth Quarter and Full Year 2025
BANNOCKBURN, Ill., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Option Care Health, Inc. (the “Company” or “Option Care Health”) (Nasdaq: OPCH), the nation's largest independent provider of home and alternate si...
Option Care Health to Participate in the TD Cowen Healthcare Conference
BANNOCKBURN, Ill., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Option Care Health, Inc. (“Option Care Health”) (Nasdaq: OPCH), the nation's largest independent provider of home and alternate site infusion servi...
Option Care Health to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call
BANNOCKBURN, Ill., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Option Care Health Inc. (“Option Care Health”) (NASDAQ: OPCH), the nation's largest independent provider of home and alternate site infusion servic...
Option Care Health Transcript: 44th Annual J.P. Morgan Healthcare Conference
Strong financial performance with double-digit growth, diversified revenue streams, and robust cash flow support continued investment in M&A, technology, and expansion. Positioned to benefit from industry shifts to lower-cost care, with minimal future impact from Stelara and biosimilars.
Option Care Health Announces Preliminary Fourth Quarter & Full Year 2025 Financial Results and Preliminary Financial Guidance for Full Year 2026
BANNOCKBURN, Ill., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Option Care Health, Inc. (the “Company” or “Option Care Health”) (Nasdaq: OPCH), the nation's largest independent provider of home and alternate si...
Option Care Health to Participate in the J.P. Morgan Healthcare Conference
BANNOCKBURN, Ill., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Option Care Health, Inc. (“Option Care Health”) (Nasdaq: OPCH), the nation's largest independent provider of home and alternate site infusion servi...
Option Care Health Transcript: Bank of America Home Care Conference
The business is positioned for above-market growth through a broad national footprint, strong payer and pharma relationships, and a robust drug pipeline. Despite a $70 million EBITDA headwind from STELARA and biosimilars in 2025, guidance for sales and earnings was raised, and ongoing industry trends favor alternate care settings and cost efficiency.
Option Care Health Transcript: BofA Securities Leveraged Finance Conference 2025
Strong financial performance and disciplined capital management have driven growth, with a focus on chronic therapies and strategic tuck-in acquisitions. Market share gains from competitor exits and robust payer relationships support ongoing expansion, while operational shifts like the Stelara transition and increased infusion suite utilization shape future outlook.
Option Care Health Transcript: Jefferies London Healthcare Conference 2025
The business is leveraging national scale and local execution to grow in both acute and chronic infusion therapies, despite headwinds from Stelara's pricing changes and biosimilar transitions. Financial guidance remains positive, with EBITDA and EPS growth expected, supported by strong cash flow and disciplined capital deployment.
Option Care Health Transcript: UBS Global Healthcare Conference 2025
Option Care Health reported strong financial performance, raising guidance for 2025 and maintaining confidence in its long-term growth algorithm despite headwinds from STELARA and biosimilar competition. Growth is driven by operational initiatives, payer partnerships, and a stable infusion suite footprint.
Option Care Health to Participate in Upcoming Investor Conferences
BANNOCKBURN, Ill., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Option Care Health, Inc. (“Option Care Health”) (Nasdaq: OPCH), the nation's largest independent provider of home and alternate site infusion servi...
Option Care Health Earnings Call Transcript: Q3 2025
Third quarter saw 12% revenue growth, strong acute and chronic therapy performance, and raised full-year guidance. Stelara biosimilar adoption remains a headwind, but operational momentum and investments in technology and clinical models support continued growth.
Option Care Health Announces Financial Results For the Third Quarter Ended September 30, 2025
BANNOCKBURN, Ill., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Option Care Health, Inc. (the “Company” or “Option Care Health”) (Nasdaq: OPCH), the nation's largest independent provider of home and alternate si...
Option Care Health Transcript: Jefferies 2025 Healthcare Services Conference
The company remains the largest U.S. home infusion provider, leveraging scale and clinical expertise to drive high single-digit revenue and double-digit EBITDA growth. A diverse drug portfolio, disciplined capital deployment, and adaptability to market changes—including biosimilar and competitor dynamics—support continued expansion and strong cash flow generation.
Option Care Health to Announce Third Quarter 2025 Financial Results and Host Conference Call
BANNOCKBURN, Ill., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Option Care Health Inc. (“Option Care Health”) (NASDAQ: OPCH), the nation's largest independent provider of home and alternate site infusion servi...
Option Care Health To Participate in Upcoming Investor Conferences
BANNOCKBURN, Ill., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Option Care Health, Inc. (“Option Care Health”) (Nasdaq: OPCH), the nation's largest independent provider of home and alternate site infusion servi...
Option Care Health Announces Chief Financial Officer Transition
Mike Shapiro to Step Down After 10 Years With the Company; Meenal Sethna Named EVP and CFO Effective October 1, 2025 Mike Shapiro to Step Down After 10 Years With the Company; Meenal Sethna Named EVP ...
Quince Therapeutics Selects Option Care Health as Specialty Infusion Therapy Provider for Administration of Lead Asset eDSP
SOUTH SAN FRANCISCO, Calif. & BANNOCKBURN, Ill.--(BUSINESS WIRE)---- $QNCX #biotech--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a ...
Option Care Health Earnings Call Transcript: Q2 2025
Second quarter saw 15%+ revenue growth, strong execution in both acute and chronic therapies, and increased full-year guidance. Investments in technology, suite-based care, and advanced practitioner models are fueling growth, with robust cash flow and active capital deployment.
Option Care Health Announces Financial Results for the Second Quarter Ended June 30, 2025
BANNOCKBURN, Ill., July 30, 2025 (GLOBE NEWSWIRE) -- Option Care Health, Inc. (the “Company” or “Option Care Health”) (Nasdaq: OPCH), the nation's largest independent provider of home and alternate si...
Option Care Health to Announce Second Quarter 2025 Financial Results and Host Conference Call
BANNOCKBURN, Ill., June 25, 2025 (GLOBE NEWSWIRE) -- Option Care Health Inc. (“Option Care Health”) (NASDAQ: OPCH), the nation's largest independent provider of home and alternate site infusion servic...
Option Care Health Transcript: Goldman Sachs 46th Annual Global Healthcare Conference
Leadership highlighted strong Q1 results and raised guidance, citing resilience and market share gains, especially in chronic therapies. Investments in people, technology, and in-house nursing drive efficiency and growth, while policy headwinds like Stelara LOE are being managed through portfolio diversity and payer negotiations.
Option Care Health Transcript: 45th Annual William Blair Growth Stock Conference
Strong Q1 growth was driven by national scale, strategic acquisitions, and robust clinical capabilities. Investments in technology, infrastructure, and payer relationships support continued expansion, while a balanced portfolio and efficient operations ensure financial resilience.